RecruitingNot ApplicableNCT06487546

Repletion of Ergothioneine in Patients With Kidney Failure


Sponsor

Stanford University

Enrollment

100 participants

Start Date

Apr 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Dialysis removes potentially harmful chemicals from the blood but can also remove potentially valuable chemicals. One potentially valuable chemical called ergothioneine, which comes from the diet, is low in the blood of people receiving dialysis. For this research study, the investigators hope to learn how well a daily ergothioneine supplement will replenish the levels in the blood of people with kidney failure.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • kidney failure receiving hemodialysis or peritoneal dialysis

Exclusion Criteria2

  • blood transfusion within 90 days
  • taking supplements which contain ergothioneine

Interventions

DIETARY_SUPPLEMENTErgothioneine

This is a 1-arm study in which participants will take ergothioneine daily with dose range of 5 mg to 25 mg daily. Blood levels of ergothioneine will be monitored while taking daily ergothioneine and after ergothioneine is stopped.


Locations(1)

Veterans Affairs Palo Alto

Palo Alto, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06487546


Related Trials